

Applicants : William C. Olson & Paul J. Maddon
Serial No. : Not Yet Known
Filed : June 15, 2000
Page 2

94 --24. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds is a nonpeptidyl molecule.--

95 --26. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds inhibits the attachment of HIV-1 to a target cell.--

96 --46. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds comprises a polypeptide which binds to a CCR5 epitope.--

97 --58. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds comprises a light chain of an antibody.--

--59. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds comprises a heavy chain of an antibody.--

--60. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds comprises the Fab portion of an antibody.--

--61. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds comprises the variable domain of an antibody.--

--62. (Amended) The composition of claim 1 [or 2], wherein at least one of the compounds comprises one or more CDR portions of an antibody.--

--63. (Amended) A method of treating a subject afflicted with HIV-1 which comprises administering to the subject an effective dose of the composition of claim

Applicants : William C. Olson & Paul J. Maddon
Serial No. : Not Yet Known
Filed : June 15, 2000
Page 3

1 [or 2].--

A7
cont
--64. (Amended) A method of preventing a subject from contracting HIV-1 which comprises administering to the subject an effective dose of the compositions of claim 1 [or 2].--

A8
--68. (Amended) An isolated nucleic acid encoding a light chain of the monoclonal antibody of [any one of] claim[s] 65[-67].--

A9
--70. (Amended) An isolated nucleic acid encoding a heavy chain of the monoclonal antibody of [any one of] claim[s] 65[-67].--

A10
--72. (Amended) One or more isolated nucleic acids encoding a Fab portion of the monoclonal antibody of [any one of] claim[s] 65[-67].--

A11
--74. (Amended) An isolated nucleic acid encoding one or more CDR regions of the monoclonal antibody of [any one of] claim[s] 65[-67].--

A12
--76. (Amended) One or more isolated nucleic acids encoding a variable domain of the monoclonal antibody of [any one of] claim[s] 65[-67].--

Remarks:

Claims 1-77 were pending in the subject application. Applicants have hereinabove canceled claims 4, 6-15, 17-19, 21-23, 25, 27-35, 37-45, 47-57, 69, 71, 73, 75, 77 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application and amended claims 3, 5, 10, 16, 24, 26, 46, 58-64, 68, 70, 72, 74 and 76. Claims 1-3, 5, 16, 20, 24, 26, 36, 46, 58-68, 70, 72, 74, 76 do not involve